Zacks Research Increases Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX) – Equities researchers at Zacks Research increased their FY2025 earnings per share (EPS) estimates for Surmodics in a research note issued to investors on Monday, November 25th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.14 per share for the year, up from their previous forecast of $0.13. The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.81 EPS.

SRDX has been the topic of several other reports. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research note on Thursday, November 7th. StockNews.com assumed coverage on Surmodics in a research note on Saturday, November 23rd. They issued a “hold” rating on the stock. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, Surmodics has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Price Performance

Shares of SRDX opened at $39.54 on Wednesday. Surmodics has a 52-week low of $25.17 and a 52-week high of $42.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.96. The business’s 50 day moving average price is $38.50 and its two-hundred day moving average price is $39.58. The firm has a market cap of $566.61 million, a PE ratio of -48.65 and a beta of 1.20.

Surmodics (NASDAQ:SRDX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.14. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%. The business had revenue of $33.23 million for the quarter, compared to analysts’ expectations of $30.69 million.

Insider Transactions at Surmodics

In other news, CFO Timothy J. Arens sold 7,009 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now directly owns 70,350 shares of the company’s stock, valued at $2,774,604. This represents a 9.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Surmodics

A number of institutional investors have recently modified their holdings of SRDX. Gabelli Funds LLC raised its position in shares of Surmodics by 393.7% during the second quarter. Gabelli Funds LLC now owns 260,200 shares of the company’s stock worth $10,939,000 after purchasing an additional 207,500 shares during the period. Gardner Lewis Asset Management L P purchased a new stake in Surmodics in the 2nd quarter valued at $8,531,000. Phocas Financial Corp. purchased a new stake in Surmodics in the 3rd quarter valued at $3,430,000. Nisa Investment Advisors LLC raised its position in Surmodics by 4,722.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company’s stock valued at $2,877,000 after buying an additional 67,010 shares during the last quarter. Finally, Versor Investments LP purchased a new stake in Surmodics in the 2nd quarter valued at $2,723,000. 96.63% of the stock is owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).